Literature DB >> 9131463

Seroepidemiology of human group C rotavirus in the UK.

V L James1, P R Lambden, E O Caul, S J Cooke, I N Clarke.   

Abstract

The gene coding for the major inner capsid protein VP6 of human group C rotavirus was cloned into baculovirus using the pBlueBac2 vector and expressed in insect cells. When cultured in High Five cells, VP6 was expressed at a high level and exported to the cell culture medium. Purified VP6 was used to immunise rabbits. Hyperimmune rabbit serum, which reacted with native human group C rotavirus in infected cells, was used to develop and optimise an EIA for the detection of antibodies to group C rotavirus using the recombinant VP6 as a source of antigen. In a local epidemiological survey of 1000 sera grouped by age, an average of 43% of samples were found to have antibodies to human group C rotavirus with the highest proportion (66%) in the 71-75 year age group. In comparison, 97% of adults and 85% of children had antibodies to recombinant VP6 from the bovine RF strain of group A rotavirus. These results suggest that infection with human group C rotavirus is a common occurrence despite the apparent rarity of reports of human group C rotavirus in clinical samples from patients with gastroenteritis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131463     DOI: 10.1002/(sici)1096-9071(199705)52:1<86::aid-jmv14>3.0.co;2-z

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  Seroepidemiology of human group C rotavirus in South Africa.

Authors:  A D Steele; V L James
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Prevalence of Rotaviruses Groups A and C in Egyptian Children and Aquatic Environment.

Authors:  Waled Morsy El-Senousy; Ahmed Mohammed El-Sayed Ragab; Eman Mohammed Abd El Hamed Handak
Journal:  Food Environ Virol       Date:  2015-02-11       Impact factor: 2.778

3.  Neutralization assay for human group C rotaviruses using a reverse passive hemagglutination test for endpoint determination.

Authors:  R Fujii; M Kuzuya; M Hamano; H Ogura; M Yamada; T Mori
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  Molecular characterization of two strains of porcine group C rotavirus.

Authors:  Sung-Geun Lee; Soo-Hyun Youn; Mi-Hwa Oh; Ok-Jae Rhee; Sangsuk Oh; Soon-Young Paik
Journal:  J Microbiol       Date:  2011-12-28       Impact factor: 3.422

5.  Detection and characterization of human group C rotaviruses in Bangladesh.

Authors:  Mustafizur Rahman; Sukalyani Banik; Abu S G Faruque; Koki Taniguchi; David A Sack; Marc Van Ranst; Tasnim Azim
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Seroepidemiology of human group C rotavirus in Japan based on a blocking enzyme-linked immunosorbent assay.

Authors:  M Kuzuya; R Fujii; M Hamano; R Ohata; H Ogura; M Yamada
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

7.  Real-time reverse transcription-PCR for detection of rotavirus and adenovirus as causative agents of acute viral gastroenteritis in children.

Authors:  Catriona Logan; John J O'Leary; Niamh O'Sullivan
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

8.  Seroepidemiology of group C rotavirus infection in England and Wales.

Authors:  Miren Iturriza-Gómara; Ian Clarke; Ulrich Desselberger; David Brown; Daniel Thomas; Jim Gray
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

9.  Incidence of group C human rotavirus in central Australia and sequence variation of the VP7 and VP4 genes.

Authors:  Roger D Schnagl; Karen Boniface; Pauline Cardwell; Damien McCarthy; Caroline Ondracek; Barbara Coulson; John Erlich; Fran Morey
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

10.  Enzyme-linked immunosorbent assay based on recombinant human group C rotavirus inner capsid protein (VP6) To detect human group C rotaviruses in fecal samples.

Authors:  V L James; P R Lambden; E O Caul; I N Clarke
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.